<DOC>
	<DOCNO>NCT01168245</DOCNO>
	<brief_summary>The aim study examine combine treatment TMS cognitive training ( CoTra ) several week produce sustain improvement cognitive behavioral symptomatology mild moderate Alzheimer 's disease ( AD ) patient .</brief_summary>
	<brief_title>TMS Stimulation Cognitive Training Alzheimer Patients</brief_title>
	<detailed_description>The current available pharmaceutical treatment Alzheimer Disease ( AD ) partially temporary effective . Therefore , new approach need . rTMS non-invasive technique generates small electric current induces modulation cortical excitability . In addition , cognitive training suggest improve cognitive function Alzheimer patient . In study intend treat mild moderate AD patient rTMS interlaced cognitive training ( rTMS- COG ) . Patients probable AD treat rTMS-COG daily 6 week follow maintenance session additional 3 month .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Male female age 5585 year Patients diagnose early moderate stage Alzheimer 's disease , accord DSMIV criterion . MMSE score 18 24 Global Dementia rating 1 2 Physically acceptable study confirm medical history exam , clinical laboratory result EKG Spouse , family member professional caregiver agree capable take care responsibility participation patient study ( answer question regard patient 's condition assume responsibility medication ) Written informed consent patient legally responsible caregiver . Able undergo MRI scan EEG recording prior onset study . Agreement participate 9 month study . Right hand Hebrew Russian mother tongue and/or ability read understand inform consent form ( ICF ) , Patient Information document Hebrew Russian . Severe agitation ; Mental retardation ; Unstable medical condition ; Use benzodiazepines hypnotic study precede two week ; Pharmacological immunosuppression ; Participation clinical trial investigational agent within two week prior study enrollment ; Alcoholism ; History Epileptic Seizures Epilepsy ; Contraindication perform MRI scanning ; Contraindication receive TMS treatment accord TMS questionnaire ; Clinically significant abnormal laboratory finding approve Principle Investigator ; Patients treat cholinesterase inhibitor , memantine ginkobiloba allow participate , treatment start least 2 month previous recruit .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Alzheimer Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Disease</keyword>
	<keyword>Cognitive Training</keyword>
	<keyword>Cortical Reorganization</keyword>
	<keyword>Brain Plasticity</keyword>
</DOC>